Tensixty
Cambridge, US · Founded 2021 · Delaware corporation · 3 known investors
Find your way into Tensixty
381 people in our graph share verified history with the Tensixty team — schools, employers, funds. One of them is your warm intro.
Paul Fieldingunlockedknows Daniel Montoro · together at UCLA (overlapped)
×7knows the team · via Broad Institute of MIT and Harvard
×2knows the team · via Harvard Medical School
×2knows the team · via UCLA
TenSixty uses machine learning and cell biology expertise to identify novel antibody targets on cancer cells for the development of new cancer therapeutics. The company combines AI with high-throughput technologies to discover improved drug candidates for oncology.
Founders & leadership
Tensixty was founded in 2021 by Daniel Montoro and Karthik Jagadeesh.
DM
Daniel MontoroinCo-founderDaniel Montoro is CEO and co-founder of TenSixty Bio, which develops antibody therapeutics for cancer using machine learning and cell biology. He completed research in stem cell and developmental biology at Stanford, Harvard, and the Broad Institute.
KJ
Karthik JagadeeshCo-founder
CM
Christoph MuusNamed on SEC filing
Board
Investors · 3
.png)
Reported raises · per SEC filings
Form D private placements$7.2M disclosed across 1 round · 2022
▶$7.2MraisedAug 2022 · 11 investors · BiotechnologyRule 506(b)
▶$7.2MraisedAug 2022 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christoph MuusDirector
- Dipchand NisharDirector
- Daniel MontoroExecutive Officer, Director
- Karthik JagadeeshExecutive Officer, Director
- Sara ChoiDirector
- Offering amount
- $7.2M
- Amount sold
- $7.2M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Tenax Therapeutics6 shared keywordsTenax Therapeutics is a clinical-stage pharmaceutical company developing TNX-103, an oral formulation of the drug levosimendan, to treat pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The company focuses on this cardiovascular and pulmonary disease, which currently has no approved treatments.
Ten63 Therapeutics5 shared keywordsTen63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets. It runs an internal pipeline of first-in-class and best-in-class programs across oncology and other serious diseases.
Tenvie4 shared keywordsTenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases. The company is led by a team with expertise in biotech and precision medicine, targeting treatments for patients and caregivers affected by neurological conditions.
Tenaya Therapeutics4 shared keywordsTenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease. This page is a board/leadership team bio page.
Day One Biopharmaceuticals3 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Octant Bio3 shared keywordsOctant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.
Dialectic Therapeutics3 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Companies competing with Tensixty for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Tensixty do?
- TenSixty uses machine learning and cell biology expertise to identify novel antibody targets on cancer cells for the development of new cancer therapeutics. The company combines AI with high-throughput technologies to discover improved drug candidates for oncology.
- Who founded Tensixty?
- Tensixty was founded by Daniel Montoro, Karthik Jagadeesh in 2021.
- Who are Tensixty's investors?
- Tensixty's investors include Civilization Ventures Management, Llc, General Catalyst, Wing.
- How much funding has Tensixty raised?
- Tensixty has disclosed $7.2M raised across 1 round.
- Where is Tensixty headquartered?
- Tensixty is headquartered in Cambridge, US.